• Something wrong with this record ?

Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration

N. Miura, K. Mori, E. Laukhtina, VM. Schuettfort, M. Abufaraj, JYC. Teoh, S. Luzzago, F. Stolzenbach, M. Deuker, PI. Karakiewicz, A. Briganti, DV. Enikeev, M. Rouprêt, V. Margulis, P. Chlosta, P. Nyirady, M. Babjuk, S. Egawa, T. Saika, SF. Shariat

. 2021 ; 51 (7) : 1149-1157. [pub] 2021Jul01

Language English Country Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc21025476

OBJECTIVE: To assess the value of preoperative albumin to globulin ratio for predicting pathologic and oncological outcomes in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy in a large multi-institutional cohort. MATERIALS AND METHODS: Preoperative albumin to globulin ratio was assessed in a multi-institutional cohort of 2492 patients. Logistic regression analyses were performed to assess the association of the albumin to globulin ratio with pathologic features. Cox proportional hazards regression models were performed for survival endpoints. RESULTS: The optimal cut-off value was determined to be 1.4 according to a receiver operating curve analysis. Lower albumin to globulin ratios were observed in 797 patients (33.6%) compared with other patients. In a preoperative model, low preoperative albumin to globulin ratio was independently associated with nonorgan-confined diseases (odds ratio 1.32, P = 0.002). Patients with low albumin to globulin ratios had worse recurrence-free survival (P < 0.001), cancer-specific survival (P = 0.001) and overall survival (P = 0.020) in univariable and multivariable analyses after adjusting for the effect of standard preoperative prognostic factors (recurrence-free survival: hazard ratio (HR) 1.31, P = 0.001; cancer-specific survival: HR 1.31, P = 0.002 and overall survival: HR 1.18, P = 0.024). CONCLUSIONS: Lower preoperative albumin to globulin ratio is associated with locally advanced disease and worse clinical outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. As it is difficult to stage disease entity, low preoperative serum albumin to globulin ratio may help identify those most likely to benefit from intensified care, such as perioperative systemic therapy, and the extent and type of surgery.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada

Department of Surgery S H Ho Urology Centre The Chinese University of Hong Kong Hong Kong China

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Ehime University Graduate School of Medicine Ehime Japan

Department of Urology European Institute of Oncology Milan Italy

Department of Urology Jagiellonian University Krakow Poland

Department of Urology Medical University of Vienna Vienna Austria

Department of Urology Semmelweis University Budapest Hungary

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital Frankfurt Frankfurt am Main Germany

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Vita Salute San Raffaele University Milan Italy

Department of Urology Weill Cornell Medical College New York USA

Division of Urology Department of Special Surgery The University of Jordan Amman Jordan

European Association of Urology Research Foundation Arnhem The Netherlands

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany

Sorbonne Université PARIS France

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025476
003      
CZ-PrNML
005      
20211026133754.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jjco/hyab023 $2 doi
035    __
$a (PubMed)33667307
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
245    10
$a Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration / $c N. Miura, K. Mori, E. Laukhtina, VM. Schuettfort, M. Abufaraj, JYC. Teoh, S. Luzzago, F. Stolzenbach, M. Deuker, PI. Karakiewicz, A. Briganti, DV. Enikeev, M. Rouprêt, V. Margulis, P. Chlosta, P. Nyirady, M. Babjuk, S. Egawa, T. Saika, SF. Shariat
520    9_
$a OBJECTIVE: To assess the value of preoperative albumin to globulin ratio for predicting pathologic and oncological outcomes in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy in a large multi-institutional cohort. MATERIALS AND METHODS: Preoperative albumin to globulin ratio was assessed in a multi-institutional cohort of 2492 patients. Logistic regression analyses were performed to assess the association of the albumin to globulin ratio with pathologic features. Cox proportional hazards regression models were performed for survival endpoints. RESULTS: The optimal cut-off value was determined to be 1.4 according to a receiver operating curve analysis. Lower albumin to globulin ratios were observed in 797 patients (33.6%) compared with other patients. In a preoperative model, low preoperative albumin to globulin ratio was independently associated with nonorgan-confined diseases (odds ratio 1.32, P = 0.002). Patients with low albumin to globulin ratios had worse recurrence-free survival (P < 0.001), cancer-specific survival (P = 0.001) and overall survival (P = 0.020) in univariable and multivariable analyses after adjusting for the effect of standard preoperative prognostic factors (recurrence-free survival: hazard ratio (HR) 1.31, P = 0.001; cancer-specific survival: HR 1.31, P = 0.002 and overall survival: HR 1.18, P = 0.024). CONCLUSIONS: Lower preoperative albumin to globulin ratio is associated with locally advanced disease and worse clinical outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. As it is difficult to stage disease entity, low preoperative serum albumin to globulin ratio may help identify those most likely to benefit from intensified care, such as perioperative systemic therapy, and the extent and type of surgery.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nefroureterektomie $7 D000074682
650    _2
$a předoperační období $7 D057234
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a sérový albumin $x analýza $7 D012709
650    _2
$a sérové globuliny $x analýza $7 D012712
650    _2
$a nádory močového měchýře $x krev $x mortalita $x patologie $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Schuettfort, Victor M $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Abufaraj, Mohammad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan
700    1_
$a Teoh, Jeremy Y C $u Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
700    1_
$a Luzzago, Stefano $u Department of Urology, European Institute of Oncology, Milan, Italy $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Stolzenbach, Franziska $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Deuker, Marina $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Briganti, Alberto $u Department of Urology, Vita Salute San Raffaele University, Milan, Italy
700    1_
$a Enikeev, Dmitry V $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Rouprêt, Morgan $u Sorbonne Université, PARIS, France
700    1_
$a Margulis, Vitaly $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Chlosta, Piotr $u Department of Urology, Jagiellonian University, Krakow, Poland
700    1_
$a Nyirady, Peter $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Babjuk, Marek $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Saika, Takashi $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u European Association of Urology Research Foundation, Arnhem, The Netherlands
773    0_
$w MED00002442 $t Japanese journal of clinical oncology $x 1465-3621 $g Roč. 51, č. 7 (2021), s. 1149-1157
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33667307 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133800 $b ABA008
999    __
$a ok $b bmc $g 1714505 $s 1145983
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 51 $c 7 $d 1149-1157 $e 2021Jul01 $i 1465-3621 $m Japanese journal of clinical oncology $n Jpn J Clin Oncol $x MED00002442
LZP    __
$a Pubmed-20211013
Back

Find record

Citation metrics

Archiving options